The diverse and crucial functions of multi-pass transmembrane proteins (TPs) make them key targets in drug development. However, their expression levels are constrained by the limited surface area of the cell membrane, and abundance is restricted to prevent cytotoxicity. Additionally, the hydrophobic transmembrane regions of these proteins are prone to aggregation and conformational changes outside the phospholipid bilayer. These challenges complicate the production of multi-pass TPs with high recovery rates, native conformations, and complete epitopes.
To support the development of drugs and therapies targeting multi-pass TPs, ACROBiosystems has established a comprehensive platform solution for the R&D and production of these proteins, including VLP technology platform, detergent micelle technology platform and Nanodisc technology platform. Through these platforms, a series of full-length multi-pass TPs has been successfully developed, including four-pass TPs like CD20, Claudin 18.2, Claudin 6, five-pass TPs like CD133, and seven-pass TPs like GPRC5D, CCR5, CXCR4, and CCR8.
Image credit: ACROBiosystems
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.